AURIGENE ONCOLOGY LIMITED
Location
Karnataka
Founded
2001-08-10
Website
Risk Signals
7 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about AURIGENE ONCOLOGY LIMITED
Live alerts from global media, monitored by Business Radar
(indiatimes.com)
Dr Reddy's Laboratories Secures Phase-2 Trial Approval for Groundbreaking CAR-T Cell Therapy | Hyderabad News - Times of India
Dr Reddy's Laboratories' subsidiary, Aurigene Oncology, has been authorized by the DCGI to initiate phase-2 trials for Ribrecabtagene autoleucel, a novel CAR-T cell therapy targeting multiple myeloma, showing promising results from earlier trials.
Read more